Literature DB >> 32105291

When Can Intermediate Outcomes Be Used as Surrogate Outcomes?

David L DeMets1, Bruce M Psaty2, Thomas R Fleming3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32105291     DOI： 10.1001/jama.2020.1176

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies.

Authors:  Oriana Ciani; Bogdan Grigore; Hedwig Blommestein; Saskia de Groot; Meilin Möllenkamp; Stefan Rabbe; Rita Daubner-Bendes; Rod S Taylor
Journal:  Med Decis Making       Date:  2021-03-10       Impact factor: 2.583

Review 2.  FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit.

Authors:  Jason S Kim; Silvana Borges; Daniel J Clauw; Philip G Conaghan; David T Felson; Thomas R Fleming; Rachel Glaser; Elizabeth Hart; Marc Hochberg; Yura Kim; Virginia B Kraus; Larissa Lapteva; Xiaojuan Li; Sharmila Majumdar; Timothy E McAlindon; Ali Mobasheri; Tuhina Neogi; Frank W Roemer; Rebecca Rothwell; Robert Shibuya; Jeffrey Siegel; Lee S Simon; Kurt P Spindler; Nikolay P Nikolov
Journal:  Semin Arthritis Rheum       Date:  2022-07-14       Impact factor: 5.431

3.  The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy.

Authors:  Florence Poizeau; Sandrine Kerbrat; Frédéric Balusson; Pierre Tattevin; Matthieu Revest; Vincent Cattoir; David Luque-Paz; Thierry Lesimple; Marc Pracht; Monica Dinulescu; David Russo; Emmanuel Oger; Alain Dupuy
Journal:  J Natl Cancer Inst       Date:  2022-05-09       Impact factor: 11.816

4.  Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions.

Authors:  Alan H Morris; Brian Stagg; Michael Lanspa; James Orme; Terry P Clemmer; Lindell K Weaver; Frank Thomas; Colin K Grissom; Ellie Hirshberg; Thomas D East; Carrie Jane Wallace; Michael P Young; Dean F Sittig; Antonio Pesenti; Michela Bombino; Eduardo Beck; Katherine A Sward; Charlene Weir; Shobha S Phansalkar; Gordon R Bernard; B Taylor Thompson; Roy Brower; Jonathon D Truwit; Jay Steingrub; R Duncan Hite; Douglas F Willson; Jerry J Zimmerman; Vinay M Nadkarni; Adrienne Randolph; Martha A Q Curley; Christopher J L Newth; Jacques Lacroix; Michael S D Agus; Kang H Lee; Bennett P deBoisblanc; R Scott Evans; Dean K Sorenson; Anthony Wong; Michael V Boland; David W Grainger; Willard H Dere; Alan S Crandall; Julio C Facelli; Stanley M Huff; Peter J Haug; Ulrike Pielmeier; Stephen E Rees; Dan S Karbing; Steen Andreassen; Eddy Fan; Roberta M Goldring; Kenneth I Berger; Beno W Oppenheimer; E Wesley Ely; Ognjen Gajic; Brian Pickering; David A Schoenfeld; Irena Tocino; Russell S Gonnering; Peter J Pronovost; Lucy A Savitz; Didier Dreyfuss; Arthur S Slutsky; James D Crapo; Derek Angus; Michael R Pinsky; Brent James; Donald Berwick
Journal:  J Am Med Inform Assoc       Date:  2021-06-12       Impact factor: 4.497

5.  Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers.

Authors:  Anthony Muchai Manyara; Oriana Ciani; Rod S Taylor
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-26

6.  Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence.

Authors:  Oriana Ciani; Bogdan Grigore; Rod S Taylor
Journal:  Health Econ       Date:  2022-05-24       Impact factor: 2.395

7.  Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol.

Authors:  Anthony Muchai Manyara; Philippa Davies; Derek Stewart; Valerie Wells; Christopher Weir; Amber Young; Rod Taylor; Oriana Ciani
Journal:  BMJ Open       Date:  2022-10-13       Impact factor: 3.006

8.  State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.

Authors:  Julia J Scialla; Jessica Kendrick; Jaime Uribarri; Csaba P Kovesdy; Orlando M Gutiérrez; Elizabeth Yakes Jimenez; Holly J Kramer
Journal:  Am J Kidney Dis       Date:  2020-08-06       Impact factor: 8.860

Review 9.  Lowering Low-Density Lipoprotein Cholesterol Concentration with Plant Stanol Esters to Reduce the Risk of Atherosclerotic Cardiovascular Disease Events at a Population Level: A Critical Discussion.

Authors:  Helena Gylling; Timo E Strandberg; Petri T Kovanen; Piia Simonen
Journal:  Nutrients       Date:  2020-08-06       Impact factor: 5.717
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.